Nektar Therapeutics Announces Start Of Phase 3 Zenith Ad Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin In Moderate-To-Severe Atopic Dermatitis
NKTR•Phase 3 program begins for rezpegaldesleukin
July 21 (Reuters) - Nektar Therapeutics NKTR.O:
- Nektar Therapeutics announces start of Phase 3 Zenith AD program evaluating novel regulatory T-cell biologic rezpegaldesleukin in moderate-to-severe atopic dermatitis
- Nektar Therapeutics - initial Phase 3 topline data expected mid-2028; BLA submission targeted for 2029
- Nektar Therapeutics - Zenith AD program to enroll 1,530 patients across three Phase 3 studies
Source text: ID:nPn5CXZNQa
Further company coverage: NKTR.O
